United States Patent 8,648,095: Lenalidomide Multiple Myeloma Claims, Scope, Expiration and Patent Landscape

US Patent 8,648,095 covers a dosing regimen for lenalidomide, marketed as Revlimid, combined with dexamethasone for multiple myeloma. Its principal limitation is a 28-day cycle consisting of lenalidomide administration for 21 consecutive days followed by seven days without lenalidomide. The patent also claims disease-stage subtypes, specific capsule strengths, excipients, dexamethasone schedules, combination therapy, and autologous stem-cell transplantation.

The patent was assigned to Celgene Corporation, now part of Bristol Myers Squibb. It issued on February 11, 2014. Public patent records identify a June 29, 2006 priority date and an expiration date in 2027, subject to the applicable patent-term adjustment and terminal-disclaimer records. The patent is one component of the broader Revlimid patent estate, which includes compound, formulation, polymorph, treatment-method and manufacturing-related rights.

What drug does US Patent 8,648,095 protect?

The claimed compound is lenalidomide, the immunomodulatory drug used in Revlimid.

Lenalidomide is a chemically modified analog of thalidomide. The patent claims the compound broadly through its chemical formula, pharmaceutically acceptable salts, solvates and stereoisomers. The supplied claim set does not reproduce the chemical structure, but the claimed strength range, capsule composition, multiple myeloma indication and dexamethasone regimen identify lenalidomide.

Item	Description
Active ingredient	Lenalidomide
Brand	Revlimid
Patent holder	Celgene Corporation; acquired by Bristol Myers Squibb
Therapeutic class	Immunomodulatory agent
Primary indication	Multiple myeloma
Dosage forms in claims	Capsules and tablets
Claimed strengths	1 mg to 50 mg; specifically 5, 10, 15 and 25 mg
Core regimen	21 days on treatment, followed by 7 days of rest
Cycle length	28 days
Combination drug	Dexamethasone
FDA status	FDA-approved product; marketed under a restricted distribution and risk-management system

FDA approved Revlimid for multiple myeloma in combination with dexamethasone and for several other hematologic indications. The commercial product is subject to the Lenalidomide REMS program, which controls prescribing, dispensing and distribution because of teratogenicity risks associated with the drug class [1].

What are the key claims of US Patent 8,648,095?

The broadest claim is claim 1. It requires all of the following:

A patient has multiple myeloma.
Lenalidomide, or a covered salt, solvate or stereoisomer, is administered.
The daily dose is approximately 1 mg to 50 mg.
Lenalidomide is administered for 21 consecutive days.
Treatment is followed by seven consecutive days without lenalidomide.
The regimen operates in a 28-day cycle.
The patient also receives a therapeutically effective amount of dexamethasone.

A generic product or treatment method that meets each limitation could fall within claim 1, unless it establishes a noninfringement or invalidity position.

How do the dependent claims narrow the patent scope?

The dependent claims add narrower patient populations, doses, dosage forms and treatment combinations.

Claim group	Subject matter
Claims 2, 10-12 and 23	Newly diagnosed, smoldering, refractory, relapsed, and relapsed-and-refractory multiple myeloma
Claims 3-6	Pharmaceutically acceptable salts and stereoisomers, including R and S isomers
Claims 7-8	Additional active agents, including melphalan, doxorubicin, vincristine, prednisone, cyclophosphamide, Biaxin and proteasome inhibitors
Claim 9	Combination with autologous stem-cell transplantation
Claims 13-14 and 24	Capsule or tablet administration; 1 mg to 50 mg capsules; specific 5, 10, 15 and 25 mg strengths
Claims 15-18	Specific daily doses of 25, 15, 10 and 5 mg
Claims 19 and 22	Dexamethasone schedules
Claims 21 and 25	Capsule formulation using lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate

The claim set is layered. Claim 1 creates the main regimen barrier. The dependent claims provide narrower fallback positions if the broad regimen claim is challenged.

What treatment regimen does the patent cover?

The central regimen is lenalidomide administered on days 1 through 21 of a 28-day cycle, followed by seven days of rest.

The claims cover doses from approximately 1 mg to 50 mg per day. The commercially important strengths are 5 mg, 10 mg, 15 mg and 25 mg. Claims 15 through 18 separately identify the principal dose levels, including 25 mg, 15 mg, 10 mg and 5 mg.

The patent also covers two dexamethasone schedules:

Claim	Dexamethasone schedule
Claim 19	40 mg per day on days 1-4 of each 28-day cycle
Claim 22	40 mg orally once daily on days 1, 8, 15 and 22 of each 28-day cycle

The distinction matters because a treatment protocol may satisfy one dexamethasone limitation but not the other. Claim 1 itself requires dexamethasone but does not specify the precise schedule. Claims 19 and 22 are narrower and require the stated schedules.

What multiple myeloma populations are covered?

The patent reaches a wide range of disease settings. The express claim language includes:

Newly diagnosed multiple myeloma
Smoldering multiple myeloma
Refractory multiple myeloma
Relapsed multiple myeloma
Relapsed-and-refractory multiple myeloma

Claims 10 through 12 and claim 23 are narrower species claims. They may remain relevant if a broader claim is found invalid or interpreted narrowly.

The inclusion of newly diagnosed disease expands the commercial relevance beyond the original relapsed or refractory market. The claims also cover treatment involving autologous stem-cell transplantation and combinations with proteasome inhibitors and conventional myeloma agents.

What formulations are protected by US Patent 8,648,095?

Claims 13, 14, 21, 24 and 25 cover oral dosage forms and a specific excipient combination.

The formulation claims identify capsules containing:

Lenalidomide
Anhydrous lactose
Microcrystalline cellulose
Croscarmellose sodium
Magnesium stearate

These claims are narrower than the regimen claim. They are directed to the composition of the capsule rather than only to the clinical use of lenalidomide.

A generic manufacturer could seek to avoid the formulation claims by using different excipients, different excipient ratios, a different dosage form or a manufacturing process that does not produce the claimed composition. That approach would not, by itself, avoid a method claim if the generic product is used according to the patented 21-days-on/seven-days-off regimen with dexamethasone.

How strong is the patent estate for Revlimid?

The Revlimid estate has historically been strong because it combines several types of rights:

Protection category	Commercial function
Compound patents	Protect lenalidomide itself
Treatment-method patents	Protect use in multiple myeloma and other hematologic diseases
Regimen patents	Protect dose, cycle and combination schedules
Formulation patents	Protect capsule compositions and dosage forms
Solid-form and polymorph patents	Protect specific physical forms
Manufacturing patents	Raise process and supply-chain barriers
Risk-management controls	Complicate generic distribution and substitution

US Patent 8,648,095 is strongest when a competitor’s proposed label, clinical protocol or actual use clearly tracks the claimed regimen. Its value is lower against a product marketed for a noninfringing indication or against a manufacturer that designs around the capsule formulation.

Method-of-treatment enforcement can be difficult where the product label does not expressly recommend the patented regimen. The risk increases when the FDA-approved label, prescribing information, pharmacy protocols and actual market use all point to 21 days of treatment followed by seven days of rest with dexamethasone.

When does US Patent 8,648,095 lose exclusivity?

US Patent 8,648,095 is publicly reported as expiring in 2027. The relevant patent-term calculation is based on the June 29, 2006 priority date, the applicable filing chain and any patent-term adjustment. The effective date should be checked against the current USPTO patent record and FDA Orange Book listing before making a launch or litigation decision [2, 3].

Exclusivity timeline

Event	Date or period
Earliest identified priority date	June 29, 2006
US patent grant	February 11, 2014
FDA approval of Revlimid for multiple myeloma	2006
Key compound and treatment patents	Expired or scheduled to expire at different times
US Patent 8,648,095	Publicly reported expiration in 2027
First limited generic entry	2022 under settlement arrangements
Broader generic access	Subject to separate settlement rights and patent restrictions

Patent expiry does not automatically eliminate all Revlimid barriers. Other unexpired patents, pediatric exclusivity, settlement restrictions, regulatory requirements and product-specific Orange Book listings can affect the practical launch date.

What is the Orange Book status of US Patent 8,648,095?

FDA Orange Book listings identify patents submitted by the NDA holder for approved drug products. Revlimid has had multiple listed patents covering the active ingredient, methods of use and related product protection.

A listed method-of-use patent can create a Paragraph IV challenge opportunity under the Hatch-Waxman Act. The generic applicant may certify that the patent is invalid, unenforceable or will not be infringed. The NDA holder can then bring patent litigation, potentially triggering a 30-month stay of approval under the statutory framework [4].

The Orange Book status of US 8,648,095 should be evaluated against:

The current Revlimid NDA listing
The patent use code
Any delisting or expiration updates
FDA-approved generic labeling
Whether the generic applicant has carved out the patented method
Whether the generic product is subject to a settlement-based launch date

The patent’s practical value depends on the relationship between the listed use code and the generic label. A narrow use-code listing may permit a skinny-label strategy. A broad method claim may still create induced-infringement risk if the generic company actively encourages the patented regimen.

Which companies challenged Revlimid patents?

Multiple generic companies filed or pursued challenges to Celgene’s Revlimid patents, including Teva, Natco, Dr. Reddy’s Laboratories, Cipla, Sun Pharmaceutical and other abbreviated new drug application sponsors.

The disputes generally involved combinations of:

Invalidity challenges
Noninfringement positions
Paragraph IV certifications
Patent-term defenses
Product and process patents
Settlement negotiations

Celgene entered settlement arrangements with several generic manufacturers. These settlements permitted limited generic access before the full expiration of the relevant patent estate. The arrangements typically restricted initial volumes and specified later dates for expanded entry.

Publicly reported commercial terms indicate that authorized or settlement-based generic lenalidomide entered the US market in limited quantities in 2022. Full-volume generic entry was tied to later contractual and patent dates, with January 31, 2026 frequently reported as a major broader-entry date for certain manufacturers [5, 6].

What patent litigation affects US Patent 8,648,095?

Revlimid patent litigation has involved a portfolio rather than a single patent. Celgene’s enforcement strategy relied on multiple patents covering the compound, methods of use, formulations and manufacturing.

The principal litigation questions for US 8,648,095 are:

Whether the proposed generic label recommends or encourages the 21/7 lenalidomide schedule.
Whether dexamethasone is included as a labeled combination therapy.
Whether the generic product is supplied in the claimed strengths.
Whether the product is used for a claimed multiple myeloma population.
Whether a capsule formulation meets the claimed excipient limitations.
Whether the claims are valid under anticipation, obviousness, written-description or enablement standards.
Whether any settlement limits the generic company’s launch rights.

A generic applicant may avoid direct infringement by carving out a patented indication or dosing instruction. That strategy does not eliminate risk where physicians are expected to prescribe the product for the patented regimen or where promotional materials, distribution controls or product labeling encourage the claimed use.

What generic launch risks exist for lenalidomide?

The generic launch risk is high because lenalidomide is an established small-molecule product with multiple ANDA filers and substantial commercial demand. The risk is moderated by the complexity of the patent estate and the settlement agreements.

Launch scenario	Effect on BMS/Celgene	Legal exposure
No generic before settlement date	Maintains high Revlimid pricing and share	Paragraph IV litigation remains the principal route
Limited settlement-based entry	Creates controlled price erosion	Volume caps and contractual restrictions apply
Skinny-label generic	Limits method-of-use exposure	Induced-infringement risk depends on label and conduct
Full generic entry after agreed date	Produces substantial price and volume erosion	Remaining patents and regulatory controls still matter
Formulation design-around	Avoids selected formulation claims	Does not necessarily avoid method claims
Noninfringing dosing label	Reduces direct label risk	Off-label use and inducement remain fact-sensitive

Because lenalidomide is orally administered and available in multiple strengths, substitution pressure can be substantial once meaningful generic supply becomes available. The REMS and controlled-distribution structure may slow early uptake but is unlikely to prevent long-term generic erosion after broad entry rights take effect.

How does US 8,648,095 compare with other Revlimid patents?

US 8,648,095 is a regimen patent rather than the foundational composition-of-matter patent.

Patent category	Typical scope	Relative strategic value
Compound patent	Lenalidomide molecule and salts	Broadest technical scope; generally earliest expiry
Multiple myeloma method patent	Lenalidomide with dexamethasone	Directly relevant to Revlimid’s core use
US 8,648,095	21/7 dosing cycle, doses, populations and combinations	Strong where the label tracks the regimen
Formulation patent	Capsule ingredients and dosage form	Design-around potential is greater
Manufacturing patent	Processes for producing lenalidomide	Relevant to API suppliers and supply-chain litigation
Polymorph or solid-form patent	Specific physical form	Depends on proof that the generic uses the claimed form

The patent is commercially important because the 21/7 schedule is closely associated with standard lenalidomide treatment. Its value is highest during the period when a generic product cannot practically enter the principal multiple myeloma market without addressing the claimed regimen.

What manufacturing and geographic barriers remain?

US 8,648,095 is a US patent. It does not directly control products sold outside the United States. Foreign counterparts must be analyzed separately by jurisdiction, including their prosecution histories, claim scope, patent-term adjustments and validity decisions.

Manufacturing barriers may arise from other patents covering:

Lenalidomide synthesis
Intermediates
Chiral resolution
Crystallization and solid forms
Impurity control
Capsule manufacture
Risk-management distribution

A company may avoid infringement of a US formulation or method claim while remaining exposed under a separate API or process patent. Global launch planning therefore requires a country-by-country freedom-to-operate review rather than reliance on the expiration of US 8,648,095 alone.

Is claim 20 legally significant?

Claim 20, as reproduced in the supplied text, states that the compound “is and is not” a pharmaceutically acceptable salt, solvate or stereoisomer. That wording is internally contradictory and appears to contain a transcription or claim-text error.

A contradiction of this kind can create indefiniteness, construction or clerical-error issues. It should not be treated as a reliable operative limitation without comparison to the USPTO-issued patent document, certified file history and any corrected patent certificate. The remaining claims do not depend on claim 20 for their legal existence.

Key Takeaways

US 8,648,095 covers lenalidomide plus dexamethasone for multiple myeloma.
The central regimen is 21 consecutive days of lenalidomide followed by seven days of rest in a 28-day cycle.
The claimed dose range is approximately 1 mg to 50 mg per day, including the commercial 5 mg, 10 mg, 15 mg and 25 mg strengths.
The patent reaches newly diagnosed, smoldering, relapsed, refractory and relapsed-and-refractory multiple myeloma.
It also claims specific dexamethasone schedules, additional active agents, autologous transplantation and a capsule formulation.
The patent was granted in 2014 and is publicly reported to expire in 2027, subject to the applicable patent-term record.
Revlimid’s commercial protection depends on a portfolio of compound, method, formulation, manufacturing and related patents.
Generic companies challenged the Revlimid estate through Paragraph IV filings and related litigation.
Settlement agreements permitted limited generic lenalidomide entry before broader market access.
Claim 20, as supplied, contains contradictory language and requires verification against the issued patent record.

FAQs About US Patent 8,648,095 and Revlimid

Does US Patent 8,648,095 cover lenalidomide itself?

No. Its primary protection is a method of treating multiple myeloma using lenalidomide and dexamethasone under a specified dosing cycle. Separate compound patents historically provided broader protection for lenalidomide itself.

Can a generic lenalidomide product avoid US 8,648,095?

Potentially. A generic company may pursue a skinny label, use a different dosing instruction or challenge the patent’s validity. Actual exposure depends on the approved label, marketing conduct, physician use and the precise claim construction.

Does the patent cover lenalidomide for lymphoma?

The supplied claims are directed to multiple myeloma. They do not expressly cover lymphoma. Other Revlimid patents and FDA-approved indications may create separate rights.

Are 5 mg and 25 mg lenalidomide capsules specifically protected?

Yes. Claims 14 and 24 identify capsules in the 5 mg, 10 mg, 15 mg and 25 mg range. Claims 21 and 25 add the specified excipient formulation.

Does FDA approval extend the patent term for US 8,648,095?

FDA approval does not automatically extend this patent. Any patent-term adjustment, patent-term extension or pediatric exclusivity must be confirmed from the USPTO and FDA records for the specific patent and NDA.

References

U.S. Food and Drug Administration. (2024). Revlimid (lenalidomide) prescribing information. https://www.accessdata.fda.gov
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,648,095, Methods of treating multiple myeloma. https://patents.google.com
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
Bristol Myers Squibb. (2021). Bristol Myers Squibb announces US settlement agreements related to Revlimid. https://news.bms.com
Securities and Exchange Commission. (2024). Bristol Myers Squibb Company annual report. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2105135	⤷ Start Trial	1590004-6	Sweden	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	C300717	Netherlands	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	CA 2015 00006	Denmark	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	92642	Luxembourg	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	C20150005 00140	Estonia	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,648,095

Summary for Patent: 8,648,095